Noise levels and their effects.
\\n\\n
Dr. Pletser’s experience includes 30 years of working with the European Space Agency as a Senior Physicist/Engineer and coordinating their parabolic flight campaigns, and he is the Guinness World Record holder for the most number of aircraft flown (12) in parabolas, personally logging more than 7,300 parabolas.
\\n\\nSeeing the 5,000th book published makes us at the same time proud, happy, humble, and grateful. This is a great opportunity to stop and celebrate what we have done so far, but is also an opportunity to engage even more, grow, and succeed. It wouldn't be possible to get here without the synergy of team members’ hard work and authors and editors who devote time and their expertise into Open Access book publishing with us.
\\n\\nOver these years, we have gone from pioneering the scientific Open Access book publishing field to being the world’s largest Open Access book publisher. Nonetheless, our vision has remained the same: to meet the challenges of making relevant knowledge available to the worldwide community under the Open Access model.
\\n\\nWe are excited about the present, and we look forward to sharing many more successes in the future.
\\n\\nThank you all for being part of the journey. 5,000 times thank you!
\\n\\nNow with 5,000 titles available Open Access, which one will you read next?
\\n\\nRead, share and download for free: https://www.intechopen.com/books
\\n\\n\\n\\n
\\n"}]',published:!0,mainMedia:null},components:[{type:"htmlEditorComponent",content:'
Preparation of Space Experiments edited by international leading expert Dr. Vladimir Pletser, Director of Space Training Operations at Blue Abyss is the 5,000th Open Access book published by IntechOpen and our milestone publication!
\n\n"This book presents some of the current trends in space microgravity research. The eleven chapters introduce various facets of space research in physical sciences, human physiology and technology developed using the microgravity environment not only to improve our fundamental understanding in these domains but also to adapt this new knowledge for application on earth." says the editor. Listen what else Dr. Pletser has to say...
\n\n\n\nDr. Pletser’s experience includes 30 years of working with the European Space Agency as a Senior Physicist/Engineer and coordinating their parabolic flight campaigns, and he is the Guinness World Record holder for the most number of aircraft flown (12) in parabolas, personally logging more than 7,300 parabolas.
\n\nSeeing the 5,000th book published makes us at the same time proud, happy, humble, and grateful. This is a great opportunity to stop and celebrate what we have done so far, but is also an opportunity to engage even more, grow, and succeed. It wouldn't be possible to get here without the synergy of team members’ hard work and authors and editors who devote time and their expertise into Open Access book publishing with us.
\n\nOver these years, we have gone from pioneering the scientific Open Access book publishing field to being the world’s largest Open Access book publisher. Nonetheless, our vision has remained the same: to meet the challenges of making relevant knowledge available to the worldwide community under the Open Access model.
\n\nWe are excited about the present, and we look forward to sharing many more successes in the future.
\n\nThank you all for being part of the journey. 5,000 times thank you!
\n\nNow with 5,000 titles available Open Access, which one will you read next?
\n\nRead, share and download for free: https://www.intechopen.com/books
\n\n\n\n
\n'}],latestNews:[{slug:"stanford-university-identifies-top-2-scientists-over-1-000-are-intechopen-authors-and-editors-20210122",title:"Stanford University Identifies Top 2% Scientists, Over 1,000 are IntechOpen Authors and Editors"},{slug:"intechopen-authors-included-in-the-highly-cited-researchers-list-for-2020-20210121",title:"IntechOpen Authors Included in the Highly Cited Researchers List for 2020"},{slug:"intechopen-maintains-position-as-the-world-s-largest-oa-book-publisher-20201218",title:"IntechOpen Maintains Position as the World’s Largest OA Book Publisher"},{slug:"all-intechopen-books-available-on-perlego-20201215",title:"All IntechOpen Books Available on Perlego"},{slug:"oiv-awards-recognizes-intechopen-s-editors-20201127",title:"OIV Awards Recognizes IntechOpen's Editors"},{slug:"intechopen-joins-crossref-s-initiative-for-open-abstracts-i4oa-to-boost-the-discovery-of-research-20201005",title:"IntechOpen joins Crossref's Initiative for Open Abstracts (I4OA) to Boost the Discovery of Research"},{slug:"intechopen-hits-milestone-5-000-open-access-books-published-20200908",title:"IntechOpen hits milestone: 5,000 Open Access books published!"},{slug:"intechopen-books-hosted-on-the-mathworks-book-program-20200819",title:"IntechOpen Books Hosted on the MathWorks Book Program"}]},book:{item:{type:"book",id:"1507",leadTitle:null,fullTitle:"Toxicity and Drug Testing",title:"Toxicity and Drug Testing",subtitle:null,reviewType:"peer-reviewed",abstract:"Modern drug design and testing involves experimental in vivo and in vitro measurement of the drug candidate's ADMET (adsorption, distribution, metabolism, elimination and toxicity) properties in the early stages of drug discovery. Only a small percentage of the proposed drug candidates receive government approval and reach the market place. Unfavorable pharmacokinetic properties, poor bioavailability and efficacy, low solubility, adverse side effects and toxicity concerns account for many of the drug failures encountered in the pharmaceutical industry. Authors from several countries have contributed chapters detailing regulatory policies, pharmaceutical concerns and clinical practices in their respective countries with the expectation that the open exchange of scientific results and ideas presented in this book will lead to improved pharmaceutical products.",isbn:null,printIsbn:"978-953-51-0004-1",pdfIsbn:"978-953-51-4363-5",doi:"10.5772/1976",price:159,priceEur:175,priceUsd:205,slug:"toxicity-and-drug-testing",numberOfPages:530,isOpenForSubmission:!1,isInWos:1,hash:"cb1ab42a370378ac16ed04066a175dfa",bookSignature:"William Acree",publishedDate:"February 10th 2012",coverURL:"https://cdn.intechopen.com/books/images_new/1507.jpg",numberOfDownloads:119242,numberOfWosCitations:225,numberOfCrossrefCitations:42,numberOfDimensionsCitations:153,hasAltmetrics:0,numberOfTotalCitations:420,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"March 9th 2011",dateEndSecondStepPublish:"April 6th 2011",dateEndThirdStepPublish:"August 11th 2011",dateEndFourthStepPublish:"September 10th 2011",dateEndFifthStepPublish:"January 8th 2012",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6,8,9",editedByType:"Edited by",kuFlag:!1,editors:[{id:"24335",title:"Prof.",name:"Bill",middleName:null,surname:"Acree",slug:"bill-acree",fullName:"Bill Acree",profilePictureURL:"https://mts.intechopen.com/storage/users/24335/images/2103_n.jpg",biography:"Dr. William Acree is currently Professor of Chemistry at the University of North Texas. He has published more than 560 scientific research articles, plus five books, six book chapters and four encyclopedia articles. He serves as a member on the Editorial Advisory Boards of eight journals and has been a manuscript reviewer for over 60 leading international journals. Professor Acree’s research interests involve developing quantitative structure-property relationships and linear free energy relationships to describe partitioning processes of chemical, environmental and pharmaceutical importance. To date he has derived expressions for predicting the solubility of drug molecules in water and in more than 70 organic solvents of varying polarity, for predicting the distribution of organic compounds and drugs between select rat (and human) tissue samples and blood, for predicting the toxicity of organic compounds to several aquatic organisms, and for predicting the solute partitioning between water and numerous organic solvents.",institutionString:null,position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"United States International University Africa",institutionURL:null,country:{name:"Kenya"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"1211",title:"Toxinology",slug:"pharmacology-toxicology-and-pharmaceutical-science-toxicology-toxinology"}],chapters:[{id:"28112",title:"Blood Brain Barrier Permeation",doi:"10.5772/20360",slug:"blood-brain-barrier-penetration",totalDownloads:6848,totalCrossrefCites:0,totalDimensionsCites:7,signatures:"Abolghasem Jouyban and Somaieh Soltani",downloadPdfUrl:"/chapter/pdf-download/28112",previewPdfUrl:"/chapter/pdf-preview/28112",authors:[{id:"34056",title:"Prof.",name:"Abolghasem",surname:"Jouyban",slug:"abolghasem-jouyban",fullName:"Abolghasem Jouyban"},{id:"38571",title:"Dr.",name:"Somaieh",surname:"Soltani",slug:"somaieh-soltani",fullName:"Somaieh Soltani"}],corrections:null},{id:"28113",title:"Diagnostic Accuracy and Interpretation of Urine Drug Testing for Pain Patients: An Evidence-Based Approach",doi:"10.5772/16692",slug:"urine-drug-testing-in-pain-patients",totalDownloads:6020,totalCrossrefCites:2,totalDimensionsCites:4,signatures:"Amadeo Pesce, Cameron West, Kathy Egan-City and William Clarke",downloadPdfUrl:"/chapter/pdf-download/28113",previewPdfUrl:"/chapter/pdf-preview/28113",authors:[{id:"26042",title:"Prof.",name:"Amadeo",surname:"Pesce",slug:"amadeo-pesce",fullName:"Amadeo Pesce"},{id:"31735",title:"Dr.",name:"Cameron",surname:"West",slug:"cameron-west",fullName:"Cameron West"},{id:"65080",title:"Dr.",name:"William",surname:"Clarke",slug:"william-clarke",fullName:"William Clarke"},{id:"65081",title:"Mrs",name:"Kathleen",surname:"Egan City",slug:"kathleen-egan-city",fullName:"Kathleen Egan City"}],corrections:null},{id:"28114",title:"Experimental and Computational Methods Pertaining to Surface Tension of Pharmaceuticals",doi:"10.5772/21005",slug:"experimental-and-computational-methods-pertaining-to-surface-tension-of-pharmaceuticals",totalDownloads:5322,totalCrossrefCites:1,totalDimensionsCites:3,signatures:"Abolghasem Jouyban and Anahita Fathi-Azarbayjan",downloadPdfUrl:"/chapter/pdf-download/28114",previewPdfUrl:"/chapter/pdf-preview/28114",authors:[{id:"34056",title:"Prof.",name:"Abolghasem",surname:"Jouyban",slug:"abolghasem-jouyban",fullName:"Abolghasem Jouyban"},{id:"41408",title:"Dr.",name:"Anahita",surname:"Fathi-Azarbayjani",slug:"anahita-fathi-azarbayjani",fullName:"Anahita Fathi-Azarbayjani"}],corrections:null},{id:"28115",title:"Multi-Well Engineered Heart Tissue for Drug Screening and Predictive Toxicology",doi:"10.5772/18501",slug:"multi-well-engineered-heart-tissue-for-drug-screening-and-predictive-toxicology",totalDownloads:2159,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Alexandra Eder, Arne Hansen and Thomas Eschenhagen",downloadPdfUrl:"/chapter/pdf-download/28115",previewPdfUrl:"/chapter/pdf-preview/28115",authors:[{id:"31696",title:"Dr.",name:"Thomas",surname:"Eschenhagen",slug:"thomas-eschenhagen",fullName:"Thomas Eschenhagen"},{id:"39303",title:"Ms.",name:"Alexandra",surname:"Eder",slug:"alexandra-eder",fullName:"Alexandra Eder"},{id:"39304",title:"Dr.",name:"Arne",surname:"Hansen",slug:"arne-hansen",fullName:"Arne Hansen"}],corrections:null},{id:"28116",title:"Prediction of Partition Coefficients and Permeability of Drug Molecules in Biological Systems with Abraham Model Solute Descriptors Derived from Measured Solubilities and Water-to-Organic Solvent Partition Coefficients",doi:"10.5772/19082",slug:"prediction-of-partition-coefficients-and-permeability-of-drug-molecules-in-biological-systems-with-a",totalDownloads:9185,totalCrossrefCites:0,totalDimensionsCites:11,signatures:"William E. Acree, Jr., Laura M. Grubbs and Michael H. Abraham",downloadPdfUrl:"/chapter/pdf-download/28116",previewPdfUrl:"/chapter/pdf-preview/28116",authors:[{id:"18022",title:"Dr.",name:"William E.",surname:"Acree, Jr.",slug:"william-e.-acree-jr.",fullName:"William E. Acree, Jr."},{id:"18027",title:"PhD.",name:"Laura",surname:"Grubbs",slug:"laura-grubbs",fullName:"Laura Grubbs"},{id:"18028",title:"Dr.",name:"Michael H.",surname:"Abraham",slug:"michael-h.-abraham",fullName:"Michael H. Abraham"}],corrections:null},{id:"28117",title:"Variability of Plasma Methadone Concentration in Opiate Dependent Receiving Methadone: A Personalised Approach Towards Optimizing Dose",doi:"10.5772/29620",slug:"variability-of-plasma-methadone-concentration-in-opiate-dependent-receiving-methadone-a-personalised",totalDownloads:2172,totalCrossrefCites:0,totalDimensionsCites:1,signatures:"Nasir Mohamad, Nor Hidayah Abu Bakar, Tan Soo Choon, Sim Hann Liang, NIM Nazar, Ilya Irinaz Idrus and Rusli Ismail",downloadPdfUrl:"/chapter/pdf-download/28117",previewPdfUrl:"/chapter/pdf-preview/28117",authors:[{id:"78599",title:"Associate Prof.",name:"Nasir",surname:"Mohamad",slug:"nasir-mohamad",fullName:"Nasir Mohamad"},{id:"90705",title:"Prof.",name:"Tan Soo",surname:"Choon",slug:"tan-soo-choon",fullName:"Tan Soo Choon"},{id:"90706",title:"Prof.",name:"Rusli",surname:"Ismail",slug:"rusli-ismail",fullName:"Rusli Ismail"},{id:"123621",title:"Dr.",name:"Nor Hidayah",surname:"Abu Bakar",slug:"nor-hidayah-abu-bakar",fullName:"Nor Hidayah Abu Bakar"},{id:"123623",title:"BSc.",name:"Hann Liang",surname:"Sim",slug:"hann-liang-sim",fullName:"Hann Liang Sim"},{id:"123626",title:"Dr.",name:"Nazar",surname:"Nim",slug:"nazar-nim",fullName:"Nazar Nim"},{id:"123627",title:"Dr.",name:"Ilya Irinaz",surname:"Idrus",slug:"ilya-irinaz-idrus",fullName:"Ilya Irinaz Idrus"}],corrections:null},{id:"28118",title:"Drug Synergy – Mechanisms and Methods of Analysis",doi:"10.5772/30922",slug:"drug-synergy-mechanisms-and-methods-of-analysis",totalDownloads:14661,totalCrossrefCites:12,totalDimensionsCites:26,signatures:"Hans-Georg Breitinger",downloadPdfUrl:"/chapter/pdf-download/28118",previewPdfUrl:"/chapter/pdf-preview/28118",authors:[{id:"84775",title:"Prof.",name:"Hans-Georg",surname:"Breitinger",slug:"hans-georg-breitinger",fullName:"Hans-Georg Breitinger"}],corrections:null},{id:"28119",title:"Herbal Medicine in the Treatment of Malaria: Vernonia amygdalina: An Overview of Evidence and Pharmacology",doi:"10.5772/30381",slug:"herbal-medicine-in-the-treatment-of-malaria-vernonia-amygdalina-an-overview-of-evidence-and-pharmaco",totalDownloads:3974,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Anoka A. Njan",downloadPdfUrl:"/chapter/pdf-download/28119",previewPdfUrl:"/chapter/pdf-preview/28119",authors:[{id:"82286",title:"Dr.",name:"Anoka",surname:"Njan",slug:"anoka-njan",fullName:"Anoka Njan"}],corrections:null},{id:"28120",title:"Experimental and Computational Methods Pertaining to Drug Solubility",doi:"10.5772/19206",slug:"experimental-and-computational-methods-pertaining-to-drug-solubility",totalDownloads:6744,totalCrossrefCites:19,totalDimensionsCites:64,signatures:"Abolghasem Jouyban and Mohammad A. A. Fakhree",downloadPdfUrl:"/chapter/pdf-download/28120",previewPdfUrl:"/chapter/pdf-preview/28120",authors:[{id:"34056",title:"Prof.",name:"Abolghasem",surname:"Jouyban",slug:"abolghasem-jouyban",fullName:"Abolghasem Jouyban"},{id:"38073",title:"Dr.",name:"Mohammad Amin",surname:"Abolghassemi Fakhree",slug:"mohammad-amin-abolghassemi-fakhree",fullName:"Mohammad Amin Abolghassemi Fakhree"}],corrections:null},{id:"28121",title:"Toxic Effects of Cadmium on Crabs and Shrimps",doi:"10.5772/29775",slug:"toxic-effects-of-cadmium-on-crabs-and-shrimps",totalDownloads:3422,totalCrossrefCites:3,totalDimensionsCites:9,signatures:"Xianjiang Kang, Shumei Mu, Wenyan Li and Na Zhao",downloadPdfUrl:"/chapter/pdf-download/28121",previewPdfUrl:"/chapter/pdf-preview/28121",authors:[{id:"79268",title:"Prof.",name:"Xianjiang",surname:"Kang",slug:"xianjiang-kang",fullName:"Xianjiang Kang"}],corrections:null},{id:"28122",title:"Paraquat, Between Apoptosis and Autophagy",doi:"10.5772/30481",slug:"paraquat-between-apoptosis-and-autophagy",totalDownloads:2622,totalCrossrefCites:0,totalDimensionsCites:1,signatures:"Rosa A. González-Polo, José M. Bravo-San Pedro, Rubén Gómez-Sánchez, Elisa Pizarro-Estrella, Mireia Niso-Santano and José M. Fuentes",downloadPdfUrl:"/chapter/pdf-download/28122",previewPdfUrl:"/chapter/pdf-preview/28122",authors:[{id:"82741",title:"Prof.",name:"Jose M",surname:"Fuentes",slug:"jose-m-fuentes",fullName:"Jose M Fuentes"},{id:"88697",title:"Dr.",name:"Rosa A.",surname:"Gonzalez-Polo",slug:"rosa-a.-gonzalez-polo",fullName:"Rosa A. Gonzalez-Polo"},{id:"88699",title:"Mr.",name:"José M",surname:"Bravo-San Pedro",slug:"jose-m-bravo-san-pedro",fullName:"José M Bravo-San Pedro"},{id:"88994",title:"Dr.",name:"Rubén",surname:"Gómez-Sánchez",slug:"ruben-gomez-sanchez",fullName:"Rubén Gómez-Sánchez"},{id:"88995",title:"Dr.",name:"Mireia",surname:"Niso-Santano",slug:"mireia-niso-santano",fullName:"Mireia Niso-Santano"},{id:"88996",title:"Ms.",name:"Elisa",surname:"Pizarro-Estrella",slug:"elisa-pizarro-estrella",fullName:"Elisa Pizarro-Estrella"}],corrections:null},{id:"28123",title:"Prediction of Toxicity, Sensory Responses and Biological Responses with the Abraham Model",doi:"10.5772/29972",slug:"prediction-of-toxicity-sensory-responses-and-biological-responses-with-the-abraham-model",totalDownloads:4020,totalCrossrefCites:0,totalDimensionsCites:6,signatures:"William E. Acree, Jr., Laura M. Grubbs and Michael H. Abraham",downloadPdfUrl:"/chapter/pdf-download/28123",previewPdfUrl:"/chapter/pdf-preview/28123",authors:[{id:"18022",title:"Dr.",name:"William E.",surname:"Acree, Jr.",slug:"william-e.-acree-jr.",fullName:"William E. Acree, Jr."},{id:"18027",title:"PhD.",name:"Laura",surname:"Grubbs",slug:"laura-grubbs",fullName:"Laura Grubbs"},{id:"18028",title:"Dr.",name:"Michael H.",surname:"Abraham",slug:"michael-h.-abraham",fullName:"Michael H. Abraham"}],corrections:null},{id:"28124",title:"Mikania glomerata and M. laevigata: Clinical and Toxicological Advances",doi:"10.5772/31735",slug:"scientific-aspects-of-mikania-glomerata-and-m-laevigata",totalDownloads:3077,totalCrossrefCites:0,totalDimensionsCites:3,signatures:"João Cleverson Gasparetto, Roberto Pontarolo, Thais M. Guimarães de Francisco and Francinete Ramos Campos",downloadPdfUrl:"/chapter/pdf-download/28124",previewPdfUrl:"/chapter/pdf-preview/28124",authors:[{id:"55129",title:"Dr.",name:"Roberto",surname:"Pontarolo",slug:"roberto-pontarolo",fullName:"Roberto Pontarolo"}],corrections:null},{id:"28125",title:"Evaluation of Drug Toxicity for DNA Vaccine Candidates Against Infectious Diseases: Hepatitis C as Experimental Model",doi:"10.5772/32320",slug:"evaluation-of-drug-toxicity-for-dna-vaccine-candidates-against-infectious-diseases-hepatitis-c-as-ex",totalDownloads:2253,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Dania Bacardí, Karelia Cosme, José Suárez, Yalena Amador-Cañizares and Santiago Dueñas-Carrera",downloadPdfUrl:"/chapter/pdf-download/28125",previewPdfUrl:"/chapter/pdf-preview/28125",authors:[{id:"90978",title:"MSc.",name:"Dania",surname:"Bacardí",slug:"dania-bacardi",fullName:"Dania Bacardí"}],corrections:null},{id:"28126",title:"Aluminium Phosphide Poisoning",doi:"10.5772/30350",slug:"aluminium-phosphide-poisoning",totalDownloads:10331,totalCrossrefCites:2,totalDimensionsCites:6,signatures:"Babak Mostafazadeh",downloadPdfUrl:"/chapter/pdf-download/28126",previewPdfUrl:"/chapter/pdf-preview/28126",authors:[{id:"82148",title:"Dr.",name:"Babak",surname:"Mostafazadeh",slug:"babak-mostafazadeh",fullName:"Babak Mostafazadeh"}],corrections:null},{id:"28127",title:"Application of a New Genotoxicity Test System with Human Hepatocyte Cell Lines to Improve the Risk Assessment in the Drug Development",doi:"10.5772/31779",slug:"application-of-a-new-genotoxicity-test-system-with-human-hepatocyte-cell-lines-to-improve-the-risk-a",totalDownloads:2799,totalCrossrefCites:0,totalDimensionsCites:1,signatures:"Tsuneo Hashizume and Hiroaki Oda",downloadPdfUrl:"/chapter/pdf-download/28127",previewPdfUrl:"/chapter/pdf-preview/28127",authors:[{id:"88651",title:"Dr.",name:"Hiroaki",surname:"Oda",slug:"hiroaki-oda",fullName:"Hiroaki Oda"},{id:"89227",title:"Dr.",name:"Tsuneo",surname:"Hashizume",slug:"tsuneo-hashizume",fullName:"Tsuneo Hashizume"}],corrections:null},{id:"28128",title:"Genotoxic Impurities in Pharmaceuticals",doi:"10.5772/24030",slug:"genotoxic-impurities-in-pharmaceuticals",totalDownloads:23250,totalCrossrefCites:2,totalDimensionsCites:3,signatures:"Abolghasem Jouyban and Hamed Parsa",downloadPdfUrl:"/chapter/pdf-download/28128",previewPdfUrl:"/chapter/pdf-preview/28128",authors:[{id:"123504",title:"Dr.",name:"Hamed",surname:"Parsa Khankandi",slug:"hamed-parsa-khankandi",fullName:"Hamed Parsa Khankandi"}],corrections:null},{id:"28129",title:"Measurement Uncertainty in Forensic Toxicology: Its Estimation, Reporting and Interpretation",doi:"10.5772/31072",slug:"measurement-uncertainty-in-forensic-toxicology-its-estimation-reporting-and-interpretation",totalDownloads:4152,totalCrossrefCites:0,totalDimensionsCites:2,signatures:"Rod G. Gullberg",downloadPdfUrl:"/chapter/pdf-download/28129",previewPdfUrl:"/chapter/pdf-preview/28129",authors:[{id:"85479",title:"Mr.",name:null,surname:"Gullberg",slug:"gullberg",fullName:"Gullberg"}],corrections:null},{id:"28130",title:"Toxicokinetics and Organ-Specific Toxicity",doi:"10.5772/30055",slug:"toxicokinetics-and-organ-specific-toxicity",totalDownloads:2116,totalCrossrefCites:0,totalDimensionsCites:1,signatures:"P.D. Ward",downloadPdfUrl:"/chapter/pdf-download/28130",previewPdfUrl:"/chapter/pdf-preview/28130",authors:[{id:"80588",title:"Dr.",name:"Peter",surname:"Ward",slug:"peter-ward",fullName:"Peter Ward"}],corrections:null},{id:"28131",title:"Environmental Toxicants Induced Male Reproductive Disorders: Identification and Mechanism of Action",doi:"10.5772/29649",slug:"environmental-toxicants-induced-male-reproductive-disorders-identification-and-mechanism-of-action-",totalDownloads:4118,totalCrossrefCites:1,totalDimensionsCites:5,signatures:"Kuladip Jana and Parimal C. Sen",downloadPdfUrl:"/chapter/pdf-download/28131",previewPdfUrl:"/chapter/pdf-preview/28131",authors:[{id:"78732",title:"Dr.",name:"Kuladip",surname:"Jana",slug:"kuladip-jana",fullName:"Kuladip Jana"}],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},relatedBooks:[{type:"book",id:"7047",title:"Botulinum Toxin",subtitle:null,isOpenForSubmission:!1,hash:"2a6791462a0bbc32c6da3218dcf5ac28",slug:"botulinum-toxin",bookSignature:"Nikolay Serdev",coverURL:"https://cdn.intechopen.com/books/images_new/7047.jpg",editedByType:"Edited by",editors:[{id:"32585",title:"Dr.",name:"Nikolay",surname:"Serdev",slug:"nikolay-serdev",fullName:"Nikolay Serdev"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"878",title:"Phytochemicals",subtitle:"A Global Perspective of Their Role in Nutrition and Health",isOpenForSubmission:!1,hash:"ec77671f63975ef2d16192897deb6835",slug:"phytochemicals-a-global-perspective-of-their-role-in-nutrition-and-health",bookSignature:"Venketeshwer Rao",coverURL:"https://cdn.intechopen.com/books/images_new/878.jpg",editedByType:"Edited by",editors:[{id:"82663",title:"Dr.",name:"Venketeshwer",surname:"Rao",slug:"venketeshwer-rao",fullName:"Venketeshwer Rao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4816",title:"Face Recognition",subtitle:null,isOpenForSubmission:!1,hash:"146063b5359146b7718ea86bad47c8eb",slug:"face_recognition",bookSignature:"Kresimir Delac and Mislav Grgic",coverURL:"https://cdn.intechopen.com/books/images_new/4816.jpg",editedByType:"Edited by",editors:[{id:"528",title:"Dr.",name:"Kresimir",surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"68579",slug:"corrigendum-to-industrial-heat-exchanger-operation-and-maintenance-to-minimize-fouling-and-corrosion",title:"Corrigendum to: Industrial Heat Exchanger: Operation and Maintenance to Minimize Fouling and Corrosion",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/68579.pdf",downloadPdfUrl:"/chapter/pdf-download/68579",previewPdfUrl:"/chapter/pdf-preview/68579",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/68579",risUrl:"/chapter/ris/68579",chapter:{id:"52929",slug:"industrial-heat-exchanger-operation-and-maintenance-to-minimize-fouling-and-corrosion",signatures:"Teng Kah Hou, Salim Newaz Kazi, Abu Bakar Mahat, Chew Bee Teng,\nAhmed Al-Shamma’a and Andy Shaw",dateSubmitted:"March 23rd 2016",dateReviewed:"October 10th 2016",datePrePublished:null,datePublished:"April 26th 2017",book:{id:"6080",title:"Heat Exchangers",subtitle:"Advanced Features and Applications",fullTitle:"Heat Exchangers - Advanced Features and Applications",slug:"heat-exchangers-advanced-features-and-applications",publishedDate:"April 26th 2017",bookSignature:"S M Sohel Murshed and Manuel Matos Lopes",coverURL:"https://cdn.intechopen.com/books/images_new/6080.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"24904",title:"Prof.",name:"S. M. Sohel",middleName:null,surname:"Murshed",slug:"s.-m.-sohel-murshed",fullName:"S. M. Sohel Murshed"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"93483",title:"Dr.",name:"Salim Newaz",middleName:null,surname:"Kazi",fullName:"Salim Newaz Kazi",slug:"salim-newaz-kazi",email:"salimnewaz@um.edu.my",position:null,institution:{name:"University of Malaya",institutionURL:null,country:{name:"Malaysia"}}},{id:"187135",title:"Ph.D.",name:"Kah Hou",middleName:null,surname:"Teng",fullName:"Kah Hou Teng",slug:"kah-hou-teng",email:"alex_teng1989@hotmail.com",position:null,institution:{name:"Liverpool John Moores University",institutionURL:null,country:{name:"United Kingdom"}}},{id:"194347",title:"Prof.",name:"Abu Bakar",middleName:null,surname:"Mahat",fullName:"Abu Bakar Mahat",slug:"abu-bakar-mahat",email:"ir_abakar@um.edu.my",position:null,institution:null},{id:"194348",title:"Dr.",name:"Bee Teng",middleName:null,surname:"Chew",fullName:"Bee Teng Chew",slug:"bee-teng-chew",email:"chewbeeteng@um.edu.my",position:null,institution:null},{id:"194349",title:"Prof.",name:"Ahmed",middleName:null,surname:"Al-Shamma'A",fullName:"Ahmed Al-Shamma'A",slug:"ahmed-al-shamma'a",email:"A.Al-Shamma'a@ljmu.ac.uk",position:null,institution:null},{id:"194350",title:"Prof.",name:"Andy",middleName:null,surname:"Shaw",fullName:"Andy Shaw",slug:"andy-shaw",email:"A.Shaw@ljmu.ac.uk",position:null,institution:null}]}},chapter:{id:"52929",slug:"industrial-heat-exchanger-operation-and-maintenance-to-minimize-fouling-and-corrosion",signatures:"Teng Kah Hou, Salim Newaz Kazi, Abu Bakar Mahat, Chew Bee Teng,\nAhmed Al-Shamma’a and Andy Shaw",dateSubmitted:"March 23rd 2016",dateReviewed:"October 10th 2016",datePrePublished:null,datePublished:"April 26th 2017",book:{id:"6080",title:"Heat Exchangers",subtitle:"Advanced Features and Applications",fullTitle:"Heat Exchangers - Advanced Features and Applications",slug:"heat-exchangers-advanced-features-and-applications",publishedDate:"April 26th 2017",bookSignature:"S M Sohel Murshed and Manuel Matos Lopes",coverURL:"https://cdn.intechopen.com/books/images_new/6080.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"24904",title:"Prof.",name:"S. M. Sohel",middleName:null,surname:"Murshed",slug:"s.-m.-sohel-murshed",fullName:"S. M. Sohel Murshed"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"93483",title:"Dr.",name:"Salim Newaz",middleName:null,surname:"Kazi",fullName:"Salim Newaz Kazi",slug:"salim-newaz-kazi",email:"salimnewaz@um.edu.my",position:null,institution:{name:"University of Malaya",institutionURL:null,country:{name:"Malaysia"}}},{id:"187135",title:"Ph.D.",name:"Kah Hou",middleName:null,surname:"Teng",fullName:"Kah Hou Teng",slug:"kah-hou-teng",email:"alex_teng1989@hotmail.com",position:null,institution:{name:"Liverpool John Moores University",institutionURL:null,country:{name:"United Kingdom"}}},{id:"194347",title:"Prof.",name:"Abu Bakar",middleName:null,surname:"Mahat",fullName:"Abu Bakar Mahat",slug:"abu-bakar-mahat",email:"ir_abakar@um.edu.my",position:null,institution:null},{id:"194348",title:"Dr.",name:"Bee Teng",middleName:null,surname:"Chew",fullName:"Bee Teng Chew",slug:"bee-teng-chew",email:"chewbeeteng@um.edu.my",position:null,institution:null},{id:"194349",title:"Prof.",name:"Ahmed",middleName:null,surname:"Al-Shamma'A",fullName:"Ahmed Al-Shamma'A",slug:"ahmed-al-shamma'a",email:"A.Al-Shamma'a@ljmu.ac.uk",position:null,institution:null},{id:"194350",title:"Prof.",name:"Andy",middleName:null,surname:"Shaw",fullName:"Andy Shaw",slug:"andy-shaw",email:"A.Shaw@ljmu.ac.uk",position:null,institution:null}]},book:{id:"6080",title:"Heat Exchangers",subtitle:"Advanced Features and Applications",fullTitle:"Heat Exchangers - Advanced Features and Applications",slug:"heat-exchangers-advanced-features-and-applications",publishedDate:"April 26th 2017",bookSignature:"S M Sohel Murshed and Manuel Matos Lopes",coverURL:"https://cdn.intechopen.com/books/images_new/6080.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"24904",title:"Prof.",name:"S. M. Sohel",middleName:null,surname:"Murshed",slug:"s.-m.-sohel-murshed",fullName:"S. M. Sohel Murshed"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"10713",leadTitle:null,title:"Trauma and Emergency Surgery",subtitle:null,reviewType:"peer-reviewed",abstract:"
\r\n\tTrauma surgery is a surgical specialty that utilizes both operative and non-operative management to treat traumatic injuries, typically in an acute setting. Emergency surgical patients often have complex and challenging problems, which may include major traumatic injury, sepsis, shock and serious abdominal conditions. For patients who have serious acute surgical or traumatic conditions inefficiencies in the system of retrieval, triage, diagnostic investigation, access to the operating theatre, and appropriate post-operative care may lead to an increased risk of morbidity and mortality. Emergency surgery includes general emergency surgery, vascular emergency surgery, thoracic emergency surgery but also urologic, cardiac, paediatric, musculoskeletal, gynaecological, transplant emergency surgery and all surgical specialties. Largely performed by surgeons specializing in emergency medicine, this surgery can be conducted for many reasons but occurs most often in urgent or critical cases in response to trauma, cardiac events, poison episodes, brain injuries, and pediatric medicine.
\r\n\r\n\tMortality rates are high for emergency surgeries. The most advanced surgical techniques are used (open surgery and laparoscopic surgery, damage control surgery for polytrauma patient management, advanced multidisciplinary management of acute and non-acute surgical patients). The Unit prides itself on the collaboration between multidisciplinary teams that make use of advanced diagnostic and therapeutic resources. General surgeons are assisted by physicians from the traditional radiology, interventional radiology, angiography and anaesthesiologists-resuscitators, to allow for a timely diagnosis and optimal treatment of urgent and non-urgent pathologies.
",isbn:"978-1-83969-524-7",printIsbn:"978-1-83969-523-0",pdfIsbn:"978-1-83969-525-4",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!0,hash:"a07902d256cd9902e2291fa7bf2322af",bookSignature:" Selim Sözen and Associate Prof. Burhan Hakan Kanat",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/10713.jpg",keywords:"Cardiovascular Surgery, Aneurysm, Bypass Surgery, Neurosurgery, Spinal Trauma, Head Injury, Orthopedics, Fracture, General Surgery, Urology, Anesthesia, Reanimation",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:null,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"February 16th 2021",dateEndSecondStepPublish:"March 16th 2021",dateEndThirdStepPublish:"May 15th 2021",dateEndFourthStepPublish:"August 3rd 2021",dateEndFifthStepPublish:"October 2nd 2021",remainingDaysToSecondStep:"14 days",secondStepPassed:!1,currentStepOfPublishingProcess:2,editedByType:null,kuFlag:!1,biosketch:"Dr. Selim Sözen is a member of the Turkish Surgical Society and International Pilonidal Society. He is an author of 105 publications including 5 book chapters, as well as a review board member of several journals.",coeditorOneBiosketch:"Dr. Burhan Hakan Kanat is a member of the Turkish Surgical Society, International Pilonidal Society, and Turkish Society of Colon and Rectal Surgery. He is an author of more than 100 publications including 5 book chapters.",coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"90616",title:null,name:"Selim",middleName:null,surname:"Sözen",slug:"selim-sozen",fullName:"Selim Sözen",profilePictureURL:"https://mts.intechopen.com/storage/users/90616/images/system/90616.jpg",biography:"Dr. Selim Sözen was born on 01.01.1973. He graduated from the Faculty of Medicine, Ondokuz Mayıs University, Turkey in 1998.\nHe trained in general surgery at Ankara Atatürk Education and Research Hospital in Turkey (2004). He worked as a specialist\nat different Government Hospitals in Turkey (2004-2013). He started to work as an Associate Professor at the Department of General Surgery of Medicine Faculty of Namık Kemal University (2013). He completed liver transplantation surgery at İnönü University (General Surgery Department, 2014–2015, Turkey) Fellowship Programs. From 2016, he has worked as a Specialist at his own clinic in İstanbul, Turkey. He is a member of the Turkish Surgical Association. His clinical interests include treatment, surgical procedures, surgical techniques, laparoscopic surgery, minimally invasive surgery, gastrointestinal surgery, hernia surgery, colorectal surgery, surgical oncology, hepatopancreatobilliary surgery, bariatric surgery for morbid obesity, bariatric medicine, endocrine surgery, esophageal diseases, breast surgery, and esophagectomy. Dr Sözen is an author of 105 publications including 5 book chapters, as well as a member of review boards of several journals",institutionString:"Sözen Surgery Clinic",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"4",totalChapterViews:"0",totalEditedBooks:"1",institution:null}],coeditorOne:{id:"183319",title:"Associate Prof.",name:"Burhan",middleName:"Hakan",surname:"Kanat",slug:"burhan-kanat",fullName:"Burhan Kanat",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRHhvQAG/Profile_Picture_1605515370315",biography:"Dr. Burhan Hakan KANAT was born on 1981 in Malatya/ Turkey. He graduated from the Faculty of Medicine, İnönü University, Turkey in 2005. He trained in general surgery at Fırat University Faculty of Medicine in Turkey (2011). He worked as a specialist at the Elazığ Training and Research Hospital in Turkey . In 2013, he received a Certificate of Surgical Competence from the Turkish Surgery Society. He completed liver transplantation surgery at İnönü University (General Surgery Department, 2014–2015, Turkey) Fellowship Programs. He received training in breast-endocrine surgery in 2016.He became an associate professor in 2017 from Head of Inter-University Council. And He worked as an Associate Professor at the Department of General Surgery of Medicine Faculty of Health Sciences University (2018-2020). He is a member of the Turkish Surgical Society , International Pilonidal Society and Turkish Society of Colon and Rectal Surgery . He started to worked as an Associate Professor at the Department of General Surgery of Medicine Faculty of Malatya Turgut Özal University (From October 2020) Dr.Kanat is an author of about more than 100 publications including 5 book chapters, as well as a member of review boards of several journals.",institutionString:"Malatya Turgut Özal University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"2",totalChapterViews:"0",totalEditedBooks:"0",institution:null},coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"16",title:"Medicine",slug:"medicine"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"347258",firstName:"Marica",lastName:"Novakovic",middleName:null,title:"Dr.",imageUrl:"//cdnintech.com/web/frontend/www/assets/author.svg",email:"marica@intechopen.com",biography:null}},relatedBooks:[{type:"book",id:"6550",title:"Cohort Studies in Health Sciences",subtitle:null,isOpenForSubmission:!1,hash:"01df5aba4fff1a84b37a2fdafa809660",slug:"cohort-studies-in-health-sciences",bookSignature:"R. Mauricio Barría",coverURL:"https://cdn.intechopen.com/books/images_new/6550.jpg",editedByType:"Edited by",editors:[{id:"88861",title:"Dr.",name:"R. Mauricio",surname:"Barría",slug:"r.-mauricio-barria",fullName:"R. Mauricio Barría"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"878",title:"Phytochemicals",subtitle:"A Global Perspective of Their Role in Nutrition and Health",isOpenForSubmission:!1,hash:"ec77671f63975ef2d16192897deb6835",slug:"phytochemicals-a-global-perspective-of-their-role-in-nutrition-and-health",bookSignature:"Venketeshwer Rao",coverURL:"https://cdn.intechopen.com/books/images_new/878.jpg",editedByType:"Edited by",editors:[{id:"82663",title:"Dr.",name:"Venketeshwer",surname:"Rao",slug:"venketeshwer-rao",fullName:"Venketeshwer Rao"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4816",title:"Face Recognition",subtitle:null,isOpenForSubmission:!1,hash:"146063b5359146b7718ea86bad47c8eb",slug:"face_recognition",bookSignature:"Kresimir Delac and Mislav Grgic",coverURL:"https://cdn.intechopen.com/books/images_new/4816.jpg",editedByType:"Edited by",editors:[{id:"528",title:"Dr.",name:"Kresimir",surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"42313",title:"HER2-Driven Carcinogenesis: New Mouse Models for Novel Immunotherapies",doi:"10.5772/53880",slug:"her2-driven-carcinogenesis-new-mouse-models-for-novel-immunotherapies",body:'The immune system might well be the best weapon against cancer, since immune defense is programmed to recognize and destroy abnormal cells infected by viruses or affected by transforming genetic or epigenetic alterations. If properly activated, a specific immune attack can be amplified and maintained long-term.These powerful mechanisms must be harnessed to fight against invadingmicroorganisms and against cancer cells, which subvert the circuits that normally control cell proliferation and survival by displaying an anarchic behavior.
Even at the start of the 20thcentury, thephysician Paul Ehrlich proposed the potential ability of the immune system to continually survey and destroy newly arising cancer cells [1]. This hypothesis represented the first version of the immune surveillance theory, formulated in 1957 by Burnet [2, 3].However, this theory was long-discredited by evidence that while the immune system can fight tumors, it is oftenunable to eradicate them. In the last decade, many cancer immunologists have shown renewed interest in immune surveillance theory, with the goal of generating novel immunotherapies against cancer, such as cancer vaccines. Advances in cancer biology, increased knowledge of immune mechanisms, and the availability of new animal models that recapitulate several human cancers have all helped to elucidate the critical issues that influence the efficacy of an immune attack against cancer [4]. This information is crucial for the rational design of cancer vaccines.
Cancer cells elaborate many defenses against immune attack. For example, they try to evade recognition by T cells and, in turn, T cell-mediated cytotoxicity, one of the major mechanisms to control tumor growth, by decreasing the expression of glycoproteins of the major histocompatibility complex (MHC) on the cell membrane [5]. In fact, the T-cell receptor (TCR) recognizes antigen only when it is displayed on the surface of the target cell as peptide fragments by the class I and class II molecules of the MHC. Moreover, the increasing instability of the genome of transformed cells favors the emergence of clones with low immunogenicity no longer expressing tumor antigens. Thus, tumors can evade immune recognition, an ability that appears to increase as a tumor grows. Finally, cancer cells suppress immune reactivity through direct release of transforming growth factor (TGF)-beta, interleukin (IL)-10, and indoleamine 2,3-dioxygenase (IDO), or through the activation of myeloid-derived suppressor cells, tumor-associated macrophages and dendritic cells to secrete these molecules. As a consequence, a tumor favors the activation and the expansion of adaptive regulatory T (Treg) cells, leading to the generation of a tolerogenic environment [6].
In these conditions, the choice of antigen is a crucial factorin deriving a cancer vaccine. Recently, Lollini et al. [7] defined the “oncoantigens” as ideal targets since these antigensare indispensible for tumor progression and thus cannot be lost, and since, depending on their localization, they can be targeted by both cytotoxic cells and antibodies. Among oncoantigens, HER2 represents a very attractive target in light of its direct association with the malignant transformation of epithelial cells and its shared presence in several human carcinomas. Indeed, vaccines targeting HER2, designed as whole cells, peptides, as well as DNA expression plasmids, are able to hamper cancer progression when used at early stages of the disease [8]. However, the promising results obtained in preclinical models are difficult to reproduce in advanced cancers, when the immune system is already severely weakened. New molecular strategies are required to generate effective cancer vaccines able to awaken the immune responses against established tumors.
HER2, also known as ErbB2 or neu in rat, is a 185-kdtransmembrane receptor with tyrosine kinase activity and initially identified in a rat glioblastoma model. HER2 belongs to the epidermal growth factor receptor (EGFR) family, which also includes HER1 (EGFR, ErbB1), HER3 (ErbB3) and HER4 (ErbB4). Each of these receptors consists of an extracellular binding domain (ECD), a single transmembrane-spanning domain, and a long cytoplasmic tyrosine kinase domain. The ECD is about 630 amino acids long and contains four subdomains arranged as a tandem repeat of a two-domain unit. The first and third subdomains (I/L1 and III/L2) have a β-barrel conformation, and the second and fourth subdomains (II/CR1 and IV/CR2) are cysteine-rich [9] (Figure 1).
Generally, binding of ligand to the extracellular region induces receptor dimerization and activation of the cytoplasmic kinase, which in turn lead to autophosphorylation and initiation of downstream signaling events. Among the EGFR family members, HER2 and HER3 are exceptional since HER3 is kinase-inactive and HER2 has no identified ligand. Although HER2 is the only receptor without a known ligand, it is the preferred partner in heterodimer formation with other HER members.
The structure of HER2. Ribbon diagram of HER2 ECD: Subdomains I (dark red), II (green), III (yellow) and IV (red), areindicated. Adapted from Cho H.S. et al., 2003 [9].
Crystallographic studies have helped to elucidate the structural basis for the differences in HER receptor function. There are two conformations of the ECD, the closed configuration and the open configuration. In the closed configuration, a dimerization arm located on domain II makes an intramolecular contact with a pocket on domain IV, preventing its association with the dimerization arms of other HER receptors and maintaining the receptor in an auto-inhibited form. Binding of its native ligand to the receptor brings domains I and III close together, switching the receptor’s conformation to the open configuration (active state), in which the dimerization arm is free to participate in receptor dimerization. Unlike the three other HER receptors, HER2 can adopt a fixed conformation resembling a ligand-activated state but permitting it to dimerize in the absence of a ligand (Figure 2). The constitutive open structure of HER2 helps to explain its readiness to interact with the ligand-activated HER receptors [10].
Receptor homo- and heterodimerization leads to the activation of downstream signaling pathways associated with cell proliferation, differentiation, survival and angiogenesis. Activation of the kinase domains by receptor dimerization and the subsequent transphosphorylation of tyrosine residues in the carboxy-terminal tails creates binding sites for several key proteins. These specific proteins activate intracellular signaling pathways, including the mitogen-activated protein kinases (Ras/Raf/MEK/MAPK) pathway, which mainly regulates cell proliferation, and the phosphoinositide 3-kinase (PI3K)–activated Akt (PI3K/Akt) pathway, which is important for cell survival [10].
Schematic overview of the structural basis for HER receptor dimerization and activation. In the ligand-free state, HER1, HER3, and HER4 have a closed conformation. Binding of ligand, involving subdomains I and III, creates an extended conformation, allowing for receptor homo- and heterodimerization. Receptor dimerization leads to C-terminal tyrosine phosphorylation, creating phosphotyrosine binding sites for binding of adaptors, signaling molecules and regulatory proteins.HER2 is unique in that it is fixed in the active conformation ready to interact with other HER receptors. Adapted from WieduwiltM. J. and Moasser M. M., 2008[10].
The HER signaling network normally governs cellular programs during development and post-natal life, but its deregulation is directly involved in the pathogenesis of several human tumors. Overexpression of HER2, enhancing and prolonging signals that trigger cell transformation, has a causal role in the promotion of carcinogenesis. The absence of the auto-inhibited conformation explains, at least in part, this HER2 transforming potential. Amplification and/or overexpression of HER2 have been reported in malignancies, such as breast, ovarian, prostate, colorectal, pancreatic and gastric cancers [11].
Breast cancer, one of the most common malignancies worldwide, is a heterogeneous disease that can be classified according to the expression of the estrogen receptor, progesterone receptor, and HER2. The resulting subgroups differ not only in clinical behavior and prognosis, but also inthe predicted response to targeted therapies against these receptors and the pathways they activate. Amplification of the HER2 gene and overexpression at the messenger RNA or protein level occurs in about 20-30% of patients with early stage breast cancer and predicts a poor prognosis [12]. Further support for the involvement of HER2 in the initiation and progression of breast cancer comes from studies on transgenic mice, although careful analysis of these transgenic mouse models suggests that overexpression of HER2, primarily due to gene amplification, is necessary but not sufficient to induce transformation. The expression of the oncoprotein induces tumors only when accompanied by genetic alterations, which include point mutations, deletions, and insertions. These alterations are invariably located in the juxtamembrane region of HER2 and lead to an unbalanced number of cysteines, potentially affecting cysteine-mediated dimerization [13].
Evidence for the insufficiency of wild-type HER2 expression, alone and without additional mutations, to induce full malignant transformation was reported by Finkle et al. [14], who found that transgenic mice overexpressing human HER2 under the murine mammary tumor virus (MMTV) promoter developed mammary tumors in a stochastic manner and after a long latency. Interestingly, those authors found sequence anomalies, including in-frame small deletions, in the juxtamembrane region of wild-type HER2 in more than half of the analyzed mammary tumors. The majority of these mutations affected the conserved cysteine residues and could function as a second hit in the transformation process, implying that additional genetic changes beyond HER2 overexpression are required for mammary tissue transformation and tumor formation. Accordingly, somatic mutations confined to the juxtamembranous region of neu have been associated with the induction of mammary tumors in neuprotooncogene transgenic mice described by Siegel et al. [15]. The relatively long latency period for the progression of these tumors seems to reflect the acquisition of activating mutations in the transgene.
Interestingly, an alternative splice form of the human HER2 gene, Δ16HER2, containing an in-frame deletion in the same region mutated in rat neu or human HER2 protooncogene transgenic mice, has been described [16]. This oncogenic isoform is clinically important and commonly coexpressed with HER2 in human breast tumors, as reported by Castiglioni et al. [17] and Mitra et al. [18], who detected Δ16HER2 transcripts in human breast carcinomas in about 10% of total HER2 transcripts. This deletion removes the relevant cysteine residues in HER2, disrupting the disulfide bond structure of the protein and leaving the remaining unpaired cysteine residues available for intermolecular bonding. Consequently, Δ16HER2, which can be defined as a normal byproduct of HER2, forms stable homodimers maintained by intermolecular disulfide bonds (Figure 3).
Δ16HER2 has increased transforming potency as compared with the wild-type HER2, as first demonstrated in vitro [17, 18]. Ectopic expression of Δ16HER2, but not wild-type HER2, promoted receptor dimerization and significantly enhanced the proliferation of murine NIH3T3 fibroblasts and human MCF-7 breast tumor cells. In addition, Δ16HER2 expression potentiated MCF-7 cell migration and invasion, whereas HER2 did not. In analysis of anchorage-independent growth as an in vitro test for tumorigenesis, both HER2 wild-type- and ∆16HER2-transfected MCF-7 cells showed enhanced colony formation in soft agar medium, but the Δ16HER2-expressing cells formed significantly larger colonies [18]. We obtained similar results with human embryonic kidney HEK293 cells stably transfected with wild-type HER2 or Δ16HER2 (Figure 4). In vivo analyses showedthat the Δ16HER2 variant is tumorigenic per se sinceathymic mice injected with Δ16HER2-expressing HEK293 transfectants developed tumors, whereas mice injected with HEK293 control cells ectopically overexpressing only wild-type HER2 did not [17]. The predicted enhanced oncogenic potential of Δ16HER2-expressing cellsin vivois supported by analysis of our newmouse model transgenically expressing the human Δ16HER2under the transcriptional control of the MMTV promoter; all of the transgenic females developed multifocal mammary tumors with a rapid onset, suggesting that the Δ16HER2 splice variant represents the transforming form of the HER2 oncoprotein [19].
Δ16HER2 splice variant. a. Schematic representation of the small region of the human HER2 genomic locus indicating the exon-intron boundaries and the alternative splicing that eliminates exon 16. The values indicated above the schematic represent nucleotide numbers corresponding to the cDNA. b. Alignment of the wild-type and alternatively spliced Δ16HER2 mRNAs; the grey box indicates sequences removed by the splicing event.
Anchorage-independent growth of stable transfected HEK293 cells. Cells expressing ∆16HER2 (b) form larger colonies than cells expressingwild-type HER2 (a).
The key role of the cysteine residues in the HER2 juxtamembrane region has been also demonstrated by Pedersen et al. [20], who described a subtype of HER2-positive tumors expressing a series of carboxy-terminal fragments collectively known as p95HER2. These fragments arise through at least two different mechanisms: proteolytic shedding of the ECD of the full-length receptor; and translation of the mRNA encoding HER2 from internal initiation codons [21]. One of these fragments, 611-CTF,which contains a transmembrane domain and a short extracellular region including the sequence deleted in Δ16HER2, is hyperactive because of its ability to form homodimers maintained by intermolecular disulfide bonds. Despite lacking the majority of the ECD, this HER2 fragment drives breast cancer progression in vivo, as shown by the development of aggressive mammary tumors in mice transgenically expressing 611-CTF andsuggesting a causal role for p95HER2 fragments in tumorigenesis based on their ability to constitutively homodimerize [20].
Together, these findings demonstrate that the overexpression of full-length HER2 alone is not sufficient to drive malignant transformation of mammary glands.
The first direct evidence for the involvement of HER2 in the initiation and progression of breast cancer came from analysis of transgenic mice with MMTV promoter-targeted overexpression of activated neu (the rat homolog of HER2) in the mammary gland. Activated neu (neu-NT) is a mutated form with valine instead of glutamic acid at residue 664 in the transmembrane domain of the protein. Although the endogenous mouse HER2 promoter has recently been used to control mammary-specific expression of activated neu-NT [22], MMTV-based mouse models have greatly increased our knowledge of the mechanisms that control HER2-mediated mammary tumor progression (Figure 5). In 1988, Leder and co-workers [23] generated the first transgenic mice that developed mammary tumors due to MMTV-driven expression of neu-NT. The short latency (11-13 weeks) and the high multiplicity of mammary tumors arising in those MMTV-neu-NT mice suggested that overexpression of the activated neu variant could drive mammary carcinogenesis in a single step.
Timeline.Several mouse models transgenic for the rat or human HER2 been generated over the past 24 years,increasing ourknowledge of the mechanisms that control HER2-mediated mammary tumour progression. Adapted from Ursini-Siegel et al., 2007 [33].
However only 1 year later, Jolicoeur’s laboratory developed a second MMTV-neu-NTtransgenic mouse model in which mammary tumor development was stochastic and with a significantlylonger latency, suggesting that mammary epithelial cells require manygenetic events in concert with neu-NToverexpression to undergo transformation [24].The differences between these two transgenicmouse models probably reflectthe ability of the transgene to integrate randomly into the mouse genome, which, in turn, influences transgene expression levels. In fact, transgenic animals generated even with the same construct may exhibit different tumor multiplicity and latency depending on the site of integrationand on thetransgene copy number. Nonetheless, subsequent studies of additional MMTV-neu-NT transgenic mice clearly demonstrated that overexpression of activatedneu is sufficient to efficiently transformmammary epithelial cells [25]. To assess the dependence of cancer cells in advanced tumors or metastaseson an initiating oncogenic event for maintenance of the transformed state, an inducible transgenic model forneu was obtained, using the tetracycline regulatory system to conditionally express activated neu in the mammary epithelium [26].In theseMMTV-rtTA/TetO-neu-NT mice, neu-initiated tumorigenesis is reversible: upon induction with doxycycline, multiple invasive mammary carcinomas developedthat regressed to a clinically undetectable state following transgene deinduction. Interestingly, most animals eventually developedneu-independent recurrent tumorslong after the apparently complete regression of their tumors, indicating thatneu-induced mammary tumors typically progress to a neu-independent state [26].
Although rapid onset of multifocal mammary tumors has been observed in the majority of activated neu transgenic mice, this mutation has never been observed in human cancers, which present only amplification of the HER2 gene copy number and consequent overexpression of HER2 protein on the cell membrane. In wild-typeneu-expressing mice under the MMTV promoter, focal mammary tumors arise next to hyperplastic mammary tissue after a long latency period (17-48 weeks) [27], suggesting that genetic alterations in addition to those inducing HER2 overexpression are required for mammary transformation. Notably, tumors in these transgenic mice arose only when the oncoprotein carried mutations in the ECD involving small deletions that promote neu transforming activity through formation of intermolecular covalent cysteine bonds [15, 28]. Accordingly, mammary epithelium-specific expression of two activated neureceptors harboring distinct in-frameneu deletions (NDL) (MMTV-neu-NDL mice) led to rapid inductionof mammary tumors [29]. Other transgenic animals with mutated forms of neu that couple specifically with Grb2 (neu-NDL-YB)or Shc (neu-NDL-YD)adaptor proteins have been generated to address the significance of HER2-coupled unique downstream signaling pathways in induction of mammary cancers [30].
More recently, after initial failed attempts [31], transgenic mice with wild-type human HER2 have been generated. A transgenic mouse expressing human HER2 under the whey acidic protein promoter was obtained, but no mammary neoplastic transformation was ever detected in any animal [32]. While another human wild-type HER2 transgenic model under the MMTV promoter did develop HER2-overexpressing breast tumors, but with a long latency of about 28.6 weeks [14]. Sequencing of the human HER2 transcripts from primary mammary tumors developed in these transgenic mice identified an in-frame 15-bp deletion in the wild-type HER2 juxtamembrane region, potentially affecting cysteine-mediated dimerization [14].
Overall, these results point to the role ofHER2-activating mutations thatchange the number of cysteines in mammarytumorigenesis. In this context, expression of the alternativelyspliced Δ16HER2 isoform, which is constitutively active by virtue of its ability toform disulfide-bridged homodimers,might be required to obtain an oncogenic phenotype. HER2 gene amplificationin primary human breast cancer mightincrease the levels of this oncogenic variantabove a critical threshold, allowingit to contribute to breast cancer progression.
The value of Δ16HER2 transgenic mouse models in addressing the biological importance of this oncogenic variant in breast cancer progression and in response to targeted therapies was suggested in 2007 by Ursini-Siegal et al. [33]. Indeed, we recently generated a mouse linetransgenically expressing human Δ16HER2, established using a bicistronic vector containing an IRES sequence between the human Δ16HER2 and the firefly luciferase gene to ensure their coordinated expression driven by the same MMTV promoter (Figure 6) [19]. Luciferase was chosen as a reporter gene since it is rapidly detectable by optical imaging in live organisms and simultaneously allows accurate quantitation in tissue extracts and immunohistochemical detection using specific antibodies.In addition, a restriction enzymePCR-based technique [34, 35] confirmed integration of the transgene at a single site on murine chromosome 5, inside an intergenic region containing neither genes nor regulatory sequences such that the insertion itself does not affect tumorigenesis. Quantitative PCR analysis revealed a transgene copy number of 5 [36] (Figure 6).
In steps to characterizeΔ16HER2 mice, we found that the founder female developed 8 spontaneous mammary tumors starting at 18 weeks of age and, as expected, readily visualized by bioluminescence analysis even one month before tumors became palpable, suggesting that luciferase expression might be predictive of tumor onset. Whole-mount and histological analysis of the mammary glands confirmed the presence of small neoplastic masses (Figure 7a). Immunohistochemical analysis of these non-palpable tumors revealed HER2 protein expression (Figure 7c), with larger tumors displaying heterogeneous membrane staining for the human transgene, while small tumors showed homogeneous distribution of HER2 in the tumor parenchyma. In all cases, HER2 expression was detected only in the mammary gland and in strict correlation with tumor development. HER2 expression also correlated with that of PCNA, a marker for mitotic activity in transformed epithelial cells (Figure 7d).
Because the MMTV promoter is hormonally regulated and tumor development in founder females might be enhanced by increased transgene expression in the mammary gland during pregnancy and lactation, we monitored spontaneous mammary tumor development by palpationin virgin female F2 transgenic mice;all of these mice developed multiple asynchronous mammary tumors (4-5 tumors/mouse) at 12 to 19 weeks of age (Figure 8c), each reaching 1-1.5 cm3 within a short time-frame (Figure 8d). Histologically, these fast-growing tumors were classified as invasive HER2-positive adenocarcinomas. Indeed, immunohistochemical analysis confirmed the concurrent expression of the human Δ16HER2 oncogene and the luciferase gene, and revealed the specific staining of epithelial cells but not of stromal cells or adipocytes, while non-neoplastic mammary ducts were negative. Tumors consisted of cells with round nuclei and eosinophilic cytoplasm growing in solid sheets and packets traversed by delicate fibrovascular septa. Growth of these unencapsulated tumors compressed the surrounding tissues (Figure 8b). Subsequent monitoring of all generations following F2 revealed similar results, indicating that formation of Δ16HER2-overexpressing mammary tumors is a reproducible phenotype in these transgenic mice.Furthermore, transgenic Δ16HER2 females bearing primary mammary tumors developed lung metastases starting at 25 weeks of age and present in 100% of mice at 36 weeks, suggesting particularly aggressive tumor behavior upon expression of the Δ16HER2 splice variant. The histological features of these pulmonary metastatic lesions were consistent with a primary breast tumor origin, with robust staining for HER2 demonstrating high-level transgene expression (Figure 9).
Bicistronic vector for Δ16HER2 mice generation.Schematic representation of the MMTV-driven human Δ16HER2-LUC transgene, with the MMTV LTR promoter (pMMTV, red), the human Δ16HER2 cDNA (green), the internal ribosome entry site(IRES, yellow), the luciferase cDNA (LUC, orange), and the termination signal from the SV40 (Poly A). Relevant restriction sites are indicated. The MMTV- Δ16HER2-IRES-LUC expression cassette (8381 bp) was isolated from the plasmid backbone by NheI and SalI digestions, purified, and microinjected into fertilized eggs from FVB females. The transgene randomly integrated at a single site (at 85.72 Mb) on murine chromosome 5 region E-1 (NT109320.4) inside an intergenic region(NCBI Build m37.1). The insertion occurred exactly 1.17 Mb downstream of the non-histone chromosomal protein HMG-17-like gene and 718 Kb upstream of the centromere protein C1 gene. Quantitative PCR analysis revealed a transgene copy number of 5.
Analysis of non-palpable tumors in Δ16HER2 transgenic mice. a. Whole-mount analysis of an inguinal mammary gland of a 14 week old mousereveals non-palpable tumors (red arrows); blue arrow indicates a limph node. Hematoxylin-eosin (b) and immunohistochemical staining for HER2 (c) and PCNA (d) of non-palpable mammary tumors at 14 weeks. Magnification: a, X6; b-d, X400.
Western analysis using lysates of cells isolated ex vivo from Δ16HER2 mice revealed a protein expression profile consistent with the immunohistochemical data, but also thepresence of some phosphorylated Δ16HER2 dimers with a higher activation status in the dimeric than the monomeric form. These findings suggest a mechanism through which the disulfide-bondedΔ16HER2 homodimeramplifies HER2 transforming potential.The same analysis showed thatSrc kinaseand several other protein mediators involved in the signaling cascade wereconsistently activated (phosphorylated), implicating this pathway in neoplastic transformation and tumor progression dynamics.
Characterization of tumorigenesis in Δ16HER2 mice. a. Primary breast tumors just before their removal from a Δ16HER2 transgenic female mouse. b. Immunohistochemical detection of HER2, revealing strong and uniform expression of HER2 protein in the mammary tumor, while the normal duct (right) is negative. Magnification: X400. c. Kaplan-Meier disease-free survival plot for F2 generation Δ16HER2-LUC transgenic mice. Mammary tumor incidence is 100% and tumor onset is from 11 to the 19 weeks (n=20). d. Tumor growth curves of five different tumors. Tumor volume was calculated as 0.5xd12xd2, where d1 and d2 are the smaller and larger diameters, respectively.
Pulmonary metastases. Hematoxylin-eosin (left) and immunohistochemical staining for HER2 (middle) and luciferase (right) in intravascular lung metastases in ∆16HER2 transgenic mice. Tumor cell aggregates are strongly positive for both human HER2 and luciferase staining. Magnification: X400.
In vitro analyses to elucidate the oncogenic mechanisms involving the Δ16HER2 splice variant will benefit from the availability of Δ16HER2-positive cell lines derived from surgically excised primary breast tumors and lung metastases fromΔ16HER2 transgenic mice. Preliminary data from our ongoing efforts to establish such lines show that these cells maintain transgene expression even after repeated passages.
Overall, the higher tumor incidence as well as the shorter latency period in Δ16HER2 transgenic mice as compared with that in the MMTV-wild-type HER2 transgenic mice described by Finkle et al. [14], together with the higher metastatic potential of the splice variant, strongly supports the candidacy of Δ16HER2 as the transforming form of the HER2 oncoprotein. Indeed, despite some similarities between the two different experimental models, i.e., use of the same mouse strain (FVB) to derive the transgenic lines, use of the same MMTV promoter, and the development of rapidly growing adenocarcinomas, these transgenic experimental systems appear to differ greatly in some features that determine tumor aggressiveness. Not only doΔ16HER2 females develop asynchronous mammary adenocarcinomas with a higher tumor incidence and a significantly shorter average latency compared to wild-type HER2 transgenic females (15.1 vs 28.6 weeks), but transgene expression in the model described by Finkle et al was detected in tumor tissue as well as in normal mammary gland and several other epithelial tissues, whereas our transgenic mice revealed strong staining for theΔ16HER2 human transgene exclusively in tumor mammary tissue, suggesting that overexpression of Δ16HER2 in the mammary gland is sufficient to induce malignant transformation in a single step. It is also noteworthy that only 5 transgene copies can drive neoplastic transformation of mammary epithelial cells compared to a relatively high number of wild-type HER2 transgene copies (30-50) necessary to induce mammary adenocarcinomas in about 80% of MMTV-wild-type HER2 transgenic mice.Since the Δ16HER2 splice variant represents about 10% of total HER2 transcript in human breast carcinoma, it is plausible that malignant transformation ensues when Δ16HER2 reaches a critical threshold in mammary cells presenting HER2 gene amplification.
The crucial role of HER2 in epithelial transformation as well as its selective overexpression in cancer tissues makes it an ideal target for cancer immunotherapy. Notwithstanding the clinically approved use of the anti-HER2 monoclonal antibody Trastuzumab, a number of concerns, including resistance, considerable costs associated with repeated treatments, and side effects, make active immunotherapies that generate polyclonal and long-lasting immune responses desirable alternative approaches.
Trastuzumab, a humanized monoclonal antibody against the ectodomain of HER2, was the first rationally designed anti-HER2 therapy approved by the US Food and Drug Administration for the clinical treatment of HER2-overexpressing breast cancer. Trastuzumab uses multiple mechanisms to interfere with HER2 downstream signaling and inhibit tumor growth, including HER2 receptor downregulation and blocking cleavage of the HER2 ECD, which otherwise leads to activation of the HER2 receptor [37]. In particular, the cytostatic effect of Trastuzumab is associated with the reduction of the signaling by the PI3K/Akt pathway and the upregulation of the cyclin-dependent kinase inhibitor p27kip1, as demonstrated by Western analysis of breast tumor cell lines treated withTrastuzumabin vitro[38].The consequences of these Trastuzumab actions are G1 arrest, reduction in cell proliferation, and apoptosis. Trastuzumab also has cytotoxic properties, such as antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-overexpressing tumor cells. ADCC is mainly due to natural killer (NK) cells which express the Fcγ receptor that binds the Fc domain of the IgG1 Trastuzumab [38].
Overall, Trastuzumab is clinically effective, but a significant proportion of HER2-overexpressing breast cancer patients either do not respond to initial Trastuzumab treatment (de novo resistance) or eventually become resistant after continuous treatment (acquired resistance). In fact, an objective response (complete + partial) when Trastuzumab is used alone is observed in only about 26% of patients with HER2-positive tumors, and many of the initial responders develop resistance in less than 6 months [39]. While higher response rates (50–80%) have been reported when Trastuzumab is used in combination with standard chemotherapy for metastatic disease, primary and acquired resistance to this reagent remains a significant clinical problem.
Understanding the molecular mechanisms of Trastuzumab resistance is crucial for the development of new therapeutic strategies and for improved survival of HER2-positive breast cancer patients. Several mechanisms have been proposed in Trastuzumab resistance [38], including steric hindrance of HER2-antibody interaction by membrane-associated glycoproteins [40], PTEN deficiency (phosphatase and tensin homolog deleted on chromosome 10) [41],increased PI3K/Akt pathway activation [42], andHER2 crosstalk with other HER members or with insulin-like growth factor-I receptor (IGF-IR) [43]. In the latter context, Huang et al. [43] showed that a heterotrimeric complex of IGF-IR, HER2 and HER3forming exclusively in Trastuzumab-resistant cells plays a key role in resistance, since knockdown of HER3 or IGF-IR by short hairpin RNA–mediated strategies upregulates p27kip1, inactivates downstream receptor signaling, and resensitizes resistant cells.
While these mechanisms may explain Trastuzumab resistance in tumors expressing only the full-length HER2 receptor, there is increasing recognition that HER2 altered forms, including p95HER2 fragments and theΔ16HER2 splice variant commonly coexpressed with wild-type protein in human tumors, play a significant role in Trastuzumab resistance. In a series of patients with HER2–positive advanced breast cancer and treated with Trastuzumab, Scaltriti et al. [44] reported that the presence of p95HER2 fragments, which lack the Trastuzumab binding domain but retain kinase activity, was associated with clinical resistance to Trastuzumab, whereas tumors expressing only the full-length receptor exhibited a high response rate to Trastuzumab. Analysis of cell lines expressing either full-length HER2 or p95HER2 confirmed the ineffectiveness ofTrastuzumab on cells expressing p95HER2 fragments [44]. Using a similar experimental approach,Mitra and coworkers [18] found that ectopic expression ofΔ16HER2, but not wild-type HER2, promotes Trastuzumab resistance in NIH3T3 fibroblasts and MCF-7 breast tumor cells; bothΔ16HER2-expressing cell typeswere refractory to Trastuzumab treatment, as shown in both cell proliferation and invasion assays, and displayed sustained oncogenic signaling. It seems likely thatΔ16HER2 expression above a critical threshold in wild-type HER2-overexpressing human breast cancercontributes to Trastuzumab resistance, consistent with clinical evidence of an inverse correlation between increased HER2 FISH ratios (>8) andTrastuzumab responsiveness [45].
Although the Trastuzumab binding site is amino-terminal to the exon 16 deletion ofΔ16HER2, Trastuzumab resistance might reflect the inefficient targeting of the splice variant receptor by the antibody because of the stable disulfide-bonded HER2 homodimers or the activation of alternative compensatory signaling pathways. In fact, Δ16HER2 harbors an in-frame deletion which promotes constitutive dimerization of the receptor andthe coupling ofΔ16HER2 to unique oncogenic signaling pathways mediated by Src kinase. Indeed, Mitra and coworkers [18] proposed Src kinase as the “master regulator” of Δ16HER2 protein signal transduction, based on the cooperation between Δ16HER2 and Src kinase as demonstrated by the ability of the Src family inhibitor dasatinib to induce Src inactivation, destabilization of Δ16HER2, and suppression of tumorigenicity. Consistent with this proposal, a recent study by Zhang et al [46] identified Src activation as a key convergence point of severalTrastuzumab resistance mechanisms, sincetargeting Src in combination with Trastuzumabresensitized multiple resistant cell lines and eliminated Trastuzumab-resistant tumors in vivo. The association between Src-mediated transduction pathways and the transforming ability of ΔHER16 in our transgenic model [19] points to the value of this model in preclinical studies to elucidate the in vivo mechanisms underlyingTrastuzumab resistance as well as the role of this variant in HER2-targeted drug responsiveness.Moreover,Δ16HER2 transgenic mice may recapitulate the clinical spectrum of Trastuzumab resistance associated with HER2-positive tumors andthusserve in testing innovative immunotherapies.
The idea of generating DNA vaccines comes from the pioneer work of Wolff and colleagues [47], who first showed that direct injection of naked DNA into the muscles of mice led to expression of the encoded reporter proteins.DNA vaccines are simple circles of DNA derived primarily from bacterial plasmids and contain a cDNAencoding thefull-length or truncated target antigen, a strong viral promoter to drive antigen expression in mammalian cells, and a polyadenylation signal (usually from bovine growth hormone or from SV40) to terminate transcription. In addition, DNA vaccines contain sequences necessary for the cloning procedures (a multiple cloning site) and for plasmid production in bacteria, consisting of the origin of replication (usually from E. coli) and an antibiotic-resistance gene to permit selective amplification of the vaccine [48] (Figure 10).
DNA vaccine backbone. pVAX1 (Invitrogen) is a 3.0 kb plasmid vector designed for use in the development of DNA vaccines and approved for such use bythe US Food and Drug Administration. Features of the vector allow high-copy number replication in E. coli and high-level transient expression of the protein of interest in most mammalian cells.The vector contains the following elements: human cytomegalovirus immediate-early (CMV) promoter for high-level expression in a wide range of mammalian cells; bovine growth hormone (BGH) polyadenylation signal for efficient transcription termination and polyadenylation of mRNA; kanamycin resistance gene for selection in E. coli; andoriginof bacterial replication (pUCori) (http://products.invitrogen.com:80/ivgn/product/V26020).
After purification (Figure 11), the DNA vaccine is commonly delivered into the skin or muscle using the biolistic system, in which compressed helium propels DNA-coated microparticles through a gene gun [49], or by simple intradermal or i.m. injection. While both delivery methods permit the introduction of DNA vaccines, the efficacy of DNA vaccination is strongly increased if it is followed by an in vivo short electric pulse, i.e., electroporation [50], which enhances DNA transfection into normal tissues by inducing transient permeability of biological membranes through the opening of microscopic pores.
Once DNA vaccines enter mammalian cells, antigen synthesis and presentation occur [48], with professional antigen-presenting cells (APCs), such as dendritic cells, presenting the transcribed and translated antigen in the context of major histocompatibility complex (MHC) and costimulatory molecules. If DNA vaccine-coded antigens are processed as endogenous intracytoplasmic proteins, the peptide fragments are presented on cellsurface MHC I molecules to cytolytic T lymphocytes (CD8+ T cells). If the antigens are secreted from the cells, they can be taken up by APCs, processed through the exogenous pathway, and presented by MHC II molecules for the activation of specific helper T cells (CD4+ T cells) which produce ‘helpful’ cytokines. For antibody responses, B cells recognize and respond to extracellularly exposed antigens, both secreted andtransmembrane proteins [48]. Through these mechanisms, DNA vaccines can elicit both cellular and humoral responses, and this combined immunity may be more effective than either arm alone.
DNA vaccines production in bacteria. Once the antigen of interest is cloned into the plasmid, the vaccine is introduced into bacterial cells, where it replicates as the bacterium multiplies. The presence of a “relaxed origin of replication” and an antibiotic-resistance gene allows efficient plasmid replication in bacterial cells and their selection, two key aspects for high-scale plasmid production. Finally, the vaccine, i.e., RHuT, can be purified using commercial kits.
The ability to induce cytotoxic responses is a distinctive property of DNA vaccines, representing the only approach other than the use of live viruses for the activation of CD8+ T cells.In addition, unlike mammalian DNA, bacterial plasmids are rich in unmethylated CpG dinucleotides, which act as a “danger signal” that warns of bacterial infection and activates the innate immune response through recognition of CpG motifs by Toll-like receptor 9 expressed on B cells and APCs. Thus, DNA vaccines are effective even when administrated without adjuvants [51].
DNA vaccines also have further distinct advantages over other vaccine prototypes, such as stability and ease of manipulation. Since the subcellular localization of the recombinant antigen dictates the type and the intensity of the immune response, it is possible to change the intracellular fate of a protein to induce selective immune responses [52, 53]. For example, signal (leader) sequences can be added or deleted from an antigen to modulate its immunogenic performance. Signal peptides, consisting of amino-terminal extensions that direct the insertion of proteins into the membrane of the endoplasmic reticulum, can be removed from secreted or membrane proteins to target them into the cytoplasm to improve antigen presentation by the MHC class I pathway and thereby enhance cytotoxic T cell induction. To optimize cytotoxic responses, an antigen can also beubiquitinated; when expressed in fusion with a target protein, ubiquitin can promote rapidproteasomal degradation of the protein, leading to MHC I peptide presentation [54]. Alternatively, CD4+ T-cell responses can be enhanced by a DNA vaccine designed to direct endogenously synthesized proteins to the lysosomal compartment of APCs, where the proteins are degraded into peptides that can be eventually loaded into the pockets of MHC class II molecules. For this purpose, a fusion construct of the full-length protein and the 20-aminoacid C-terminal tail of lysosomal integral membrane protein-II (LIMP-II)has been used [55]. To favor the antibody response, signal sequences, usually of 16 to 30 amino acid residues comprising a central hydrophobic core and a C-terminal region with the cleavage site for signal peptidase, can be cloned in-frame with the sequence encoding a cytoplasmic protein, driving it toward the plasma membrane.
Recently, we have conceived a new kind of DNA vaccine that combines antigen expression with the silencing of molecules involved in the immunosuppression exerted by growing cancers. This double action is associated with two distinct modules: one is the conventional antigen expression cassette, while the other generates short hairpin (sh)RNA under the control of a polymerase III promoter [56, 57]. The RNA interference with synthesis of negative immune regulators, such as IDO or IL-10, is expected to ensure optimal presentation of the encoded antigen by APCs.
While the success of vaccination in preventing infectious diseases is uncontested, the derivation of efficient vaccines against cancer represents a more difficult challenge. Although cancer cells express antigens in a way that distinguishes them immunologically from normal cells, most tumors are only weakly immunogenic because most tumor antigens are "self" proteins and generally tolerated by the host. Thus, an effective cancer vaccine must activate the immune system to react against tumor–associated molecules and, in some cases, overcome immunological tolerance to such molecules.This implies a vaccine-stimulated immune reaction in patients showing no or only a weak pre-existing immune response against the tumor antigen [58].
The HER2oncoantigenis considered an ideal target for DNA vaccination because it is directly involved in cancer progression and because itplays a causal role in the transformed phenotype, restricting the emergence of antigen-loss variants. HER2 overexpression in several carcinomas with an aggressive course, unlike its expression in normal tissues, ensures a specific anti-cancer response and minimal risk of an autoimmune attack on healthy tissues. Finally, HER2 is exposed on the cell membrane and can thus be readily targeted by antibodies and cell-mediated immunity [5]. On the other hand, HER2 is a “self” molecule, such that triggering a response to it must circumvent tolerance mechanisms.
An abundance of experiments in preclinical models demonstrates the promise of DNA vaccination as an effective approach to prevent the development of HER2-positive tumors, eliciting immune protection against spontaneous mammary carcinomas in mice transgenic for the rat HER2 oncogene as well as in transplantable rat and human HER2-expressing tumors [59-65]. As we specifically documented [63], anti-HER2 antibody production after vaccination represents the main mechanism responsible for the anti-tumor response. In fact, anti-HER2 antibodies are able to downmodulate the expression of this growth factor receptor causally implicated in carcinogenesis. Indirect reactions, such as ADCC and complement-mediated cytotoxicity, are also crucial in preventing the onset of a tumor and controlling its progression.
As mentioned above, DNA vaccines are easily manipulated to optimize immune activation using recombinant DNA technologies. In one of the first studies of HER2-targeted DNA vaccination, the plasmid encoding the extracellular and transmembrane (EC-TM) domains of this molecule proved to be far superior to plasmids encoding only the extracellular domain (secreted form) or the full-length protein [59]. Most subsequent studies, performed in both wild-type BALB/c mice and cancer-prone BALB-neuT transgenic mice, confirmed the unique ability of this vaccine to trigger protective immunity toward rat HER2-positive tumors [60-63]. BALB-neuT mice transgenically expressing the rat activated neu oncogene under the control of the MMTV promoter are genetically predestined to develop lethal invasive carcinomas in the mammary glandsat high multiplicity (all mammary glands are affected) and with relatively short latency [66]. About 50% of BALB-neuT mice electroporatedwith EC-TM plasmid when the mammary glands display atypical hyperplasia, at 10 and 12 weeks of age,remained free of autochthonous mammary tumors up to at least 1 year of age, whereas all unvaccinated mice succumbed to mammary cancer within 22–27 weeks [62].
In efforts to define the minimal antigen portion still able to elicit protective immunity, we carried out molecular dissection of the HER2 molecule through sequential deletions of multiples of 240 bp, corresponding to 80 amino acids, starting from the amino-terminal of the extracellular sequence [63]. The resulting seven cut-down fragments were cloned into a recipient expression vector downstream of the leader sequence, which drives the proteins through the endoplasmic reticulum toward the plasma membrane (Figure 12).
A first series of DNA vaccination experiments with these seven cut-down plasmids was performed in wild-type BALB/c mice transplanted with syngeneic rat HER2-positive adenocarcinoma cells, established from a mammary tumor of BALB-neuT mice (TUBO cells). Significant protection was obtained in mice immunized with the first four cut-down plasmids, while protection declined in mice immunized with shorter fragments. In particular, EC4-TM, which lacks almost half of the EC domain and exposes only 344 amino acids, protected all vaccinated mice through the induction of anti-rat HER2 antibodies at levels comparable to those in mice vaccinated with the whole EC-TM [63]. However, in wild-type BALB/c mice, vaccination triggered a strong immune response because the rat HER2 protein target is a foreign, xenogeneic antigen. It is much more difficult to induce immunoprotection in cancer-prone BALB-neuT mice, which are tolerant to rat HER2 protein because they express the transgene in the thymus early in life [67]. In those mice, only electroporation with EC-TM or EC4-TM led to a significant delay in the progression of mammary lesions, whereas the other cut-down plasmids were completely ineffective. Interestingly, EC4-TM induced a stronger ADCC response than did the whole EC-TM, suggesting that EC4-TM provides accessible critical determinants that may be partially masked in the whole EC-TM [63]. Together, the results of these experiments suggest that the first 390 amino acids of HER2 are those responsible for triggering the protective immunity induced by EC-TM vaccination.
HER2 cut-down vaccines. The seven cut-down HER2 DNA fragments were inserted downstream of the leader sequence using EcoRI and XbaI restriction enzymes. The truncated protein encoded by the first cut-down plasmid (EC1-TM) displays an EC domain lacking the first 70 NH2-terminal residues. All the other truncated proteins, encoded respectively by the EC2-TM, EC3-TM, EC4-TM, EC5-TM, EC6-TM, and EC7-TM cut-down plasmids, display EC domains progressively shortened by 80 NH2-terminal residues. All of these truncated proteins have an identical TM domain.
In a strategy aimed at breaking the tolerance to HER2 and further improving the elicited protection in BALB-neuT mice, we constructed two new DNA vaccines, RHuT and HuRT, encoding rat and human HER2 chimeric proteins. Containing both syngeneic and xenogeneic portions of the protein antigen, they ensurespecificity as well as a tolerance break [64, 65]. In particular, HuRTwas derived by cloning the human cDNA fragment encoding the first 390 amino-terminal residues into the rat EC5-TM cut-down plasmid to regenerate the whole EC domain. Almost symmetrically, RHuT encodes a protein in which the 410 amino-terminal residues are from the rat HER2 and the remaining residues from human HER2 (Figure 13 and Figure 14).
RHuT electroporation. RHuTencodes for a chimeric protein inwhich the 410 NH2-terminal residues are from the rat HER2 extracellular domain and the remaining residues from the human protein. After i.m. injectionof 50 μg of DNA plasmid,two low voltage pulses of 150V of 25 ms with a 300μs interval were applied through the insertion ofCliniporator needles (Igea, Carpi, Italy) into the mouse quadriceps muscles.
Presentation of xenogeneic peptides by dendritic cells (DC) contributes to an antibody response to both the tolerated and non-tolerated moieties of the antigen. Following DNAelectroporation (a) with RHuTplasmid encoding for a rat (orange) and human (blue) chimeric HER2 protein, T cells (T) recognizing the xenogeneic peptides proliferate. The expanded T cells interact and provide helper signals to B cells,leading to the production of antibodies (Y) to both the xenogeneic and tolerated moietiesby plasmacells (PC). Adapted from Iezzi M. et al, 2012 [68].
Chimeric vaccines displayed superior performance in tolerant BALB neu-T mice[64, 65]. While control mice vaccinated with empty pVAX plasmid developed HER2-positive mammary tumors within 27 weeks of age, all mice electroporatedat 10 weeks and at 12 weeks of age with RHuT or fully rat EC-TM (RRT) remained tumor-free at 40 weeks. However, 10 weeks later,the protection of mice vaccinated with RRT decreased to about 50%, while 80% of RHuT vaccinated mice remained tumor-free (Figure 15a). In both cases, the tumor rejection pattern correlated with higher titers of anti-rat HER2 antibodies (Figure 15b). In addition, RHuT protection could be further extendedby repeated boosting to maintain immunological memory [64].
Preclinical data obtained with RHuT provided the rationale for its use in an ongoing phase I clinical trial (EudraCT 2011-001104-34) approved by Italian Ministry of Health in HER2-positive head-and-neck cancers (protocol code: IOV-HN-1-2011). Moreover, preliminary data have shown that chimeric vaccines used in Δ16HER2 transgenic mice are also able to counteract the aggressive breast carcinogenesis driven by theΔ16HER2 splice variant.
Vaccination with RHuT effectively protects Balb-neuT mice from HER2-driven mammary carcinogenesis. a. Mammarytumorincidence of BALB-neuT vaccinated mice with RHuT (dotted red line, n = 7 mice), RRT(continuous red line, n = 8 mice), and empty control pVAX (dotted black line, n = 6 mice). Differences intumor incidence were analyzed by the log-rank (Mantel-Cox) test. b. Mouse sera collected 2 weeks after the second vaccination were analyzed for anti-rat HER2 antibody titerby flow cytometry (b).Data are mean MFI ± SEM (* p = 0.02, Student’s t test).
Breast cancer remains one of the major causes of morbidity and mortality in Western Countries, despite progress in both knowledge and treatment. A deeper understanding of the underlying biology of breast cancer is necessary for the identification of new molecular targets and development of novel targeted therapeutics.
In the last three decades, a large number of transgenic mice have been generated that demonstrate the direct involvement of the HER2 receptor in mammary carcinogenesis. In these cancer-prone mice transgenically expressing the rat or human HER2 molecule, the development of autochthonous tumors recapitulates several of the molecular and genetic features of human cancer progression. Some of these animal models support the hypothesis that overexpression of HER2 alone is not sufficient to generate mammary tumors and requires activating mutations.
Emerging evidence indicates that theΔ16HER2 splice variant plays a key role in tumor progression and refractoriness to Trastuzumab treatment. Currently, a new mouse model transgenic for the human Δ16HER2 isoform is available. While no single genetically engineered mouse can offer a complete model of the wide assortment of human neoplasms found in human breast cancer, theΔ16HER2 mouse represents a novel tool to test the ability of drugs and vaccines to inhibit the progression of HER2-driven cancer and to investigate Trastuzumab resistance.
Among targeted therapies being developed for breast cancer, anti-HER2 cancer vaccines seem particularly promising.
However, the generation of an effective vaccine able to trigger a long-lasting immunity that prevents tumor recurrence in cancer patients implies the understanding of how tolerance, immunity and immune suppression regulate antitumor immune responses. Equally important for the rational design of cancer vaccines is the development of new biotechnological tools for the identification of the most immunogenic portions of a molecule and for the selection of the key epitopes within a protein.
In Steven Spielberg’s “War of the Worlds”, mankind prevailed over extraterrestrial invaders thanks to immunity, because “For neither do men live nor die in vain." The challenge is to redirect the powerful mechanisms of the immune response, so effective against outside invaders such as microorganisms, against an inside enemy, i.e., cancer.
The experimental data hereinwere obtained through grants from the Italian Association for Cancer Research (AIRC, IG11889) and the Italian Ministry for the Universities and Research. We thank Prof. Guido Forni for being a beacon in our scientific life.
It is important to consider that, after vision, the ear is the most important sensory organ of the human body. The ear is an alarm sensor; that is, it is always active to perceive sounds. The sound consists in the change of air pressure that produces waves with a certain periodic frequency. However, within these there are also sound signals that are inarticulate to the human ear and also unpleasant, even damaging human health. Any sound pressure in the air is measured in decibels. A decibel is a logarithmic value (not linear, but exponential) that represents the relationship between a measured value and a reference value. In any environment there are audible signals that we need to perceive (talks, alarms, etc.) and other unwanted signals that cause the so-called noise pollution. The said contamination is defined as the presence of noise caused by an acoustic emitter that implies discomfort or harm to the health of people.
\nSome of the noises to which the human auditory system is exposed and that are part of the noise pollution are the following:
Noises due to the use of musical instruments
Use of household appliances such as washing machines, vacuum cleaners, etc.
Noises of air conditioning equipment
Discomfort caused by infrastructure
Dogs barking in the absence of their master
Alarms and sirens caused by fixed sources and mobile sources
Noise pollution significantly interferes with interpersonal communication and increases workplace accidents and traffic accidents. Table 1 shows the noise levels and their effects on the human ear.
\nNoise levels and their effects.
A filter may consist of hardware or software applied to a set of noisy or contaminated data in order to extract information of interest. Noise can be generated by any source. In this chapter, a digital solution is proposed that allows the attenuation of noise attached to audible signals that are perceived by the human ear. An adaptive filter is a device that is useful for processing an input signal by blocking and/or allowing some parts of it (unwanted noise or vibration).
\nOn the other hand, the adaptive filter [1] has a feedback loop that has the ability to minimize the error produced by the comparison between the output signal (after processing) and a reference signal (expected signal). The above allows to guarantee that the human ear is not contaminated with the unwanted signals and only to rescue the information that needs to be received. Figure 1 shows the structure of an adaptive filter.
\nGeneric structure of an adaptive filter.
The signal d(n) is the expected audio signal to be perceived by the human ear, x(n) is the input signal to the filter (what is perceived from the environment), y(n) is the response signal that grants the filter, and e(n) is the error required to adapt the filter parameters by comparing the desired signal with that obtained. This comparison is the difference between the desired (reference) signal with respect to the signal obtained at the filter output.
\nThe operation of the algorithm that will represent the filter [2] is as follows:
The input signal will be picked up (in the scheme it is labeled as x(n)). This signal is the one that is in the environment and that contains what you want to be perceived and the adhered noise.
There is a reference signal labeled with d(n). This signal is what is expected to be perceived by the human ear, for example, the conversation you have with the person with whom you are talking.
The signal x(n) is processed in order to attenuate unwanted signals (noises that may be high or low frequencies) in order to obtain y(n).
The output signal y(n) and the desired d(y) are compared in order to obtain an error that should be the minimum possible.
Based on the error generated, the process will be carried out again to ensure that the signal obtained after the filter is as close as possible to the reference signal.
In general, the filter [3] will be used to inhibit signals that are not desired (technically this process is known as attenuating the amplitude of the noise signal) to “clean” the signal that must be perceived by the human ear. The proposed technique adapts to the conditions of the environment in which it is being implemented.
\nSection 2 shows the development of the proposal; the equipment required for its implementation and its constituent parts are defined.
\nThe design of the proposal will be partitioned in stages. Each stage involves material and equipment required for the tests, measurements, and results obtained. Figure 2 shows the process diagram that will follow the treatment of the signal captured from the environment.
\nGeneral processing diagram.
The general processing diagram shown in Figure 2 consists of five stages which will be explained below:
\nStage A. It consists of the acquisition of the audible signal that is recovered from the environment. The use of an omnidirectional microphone is feasible here, the foregoing because the audio signal can be obtained from any point but not from a specific one. A microphone is a transducer device that converts sound waves into electrical voltage changes. In simple words, the microphone will record all the signals captured from any side from where they are received since the entire microphone structure is sensitive to sound. Next, Figure 3 shows the pickup pattern of an omnidirectional microphone.
\nOmnidirectional pickup pattern in a microphone.
It should be mentioned that an omnidirectional pickup pattern captures the sound obtained from any direction.
\nIt is important to capture all the sounds of the environment. For example, if a person is going to cross the street, it is important that he consider the sounds of fenced cars and be attentive to all perceived sounds in order to avoid an accident. The proposal to be designed will minimize the sound intensity of these noises but not completely mitigate them.
\nThe proposal will capture all the random noises in the environment and process them, and when it detects that there is one that exceeds the threshold of intensity allowed, it will multiply it by a reduction factor and thus decrease its volume. The process described above is purely adaptive, which means that “n” number of repetitions will be performed until it approaches the expected result.
\nStage B. The signal captured in Stage A is of analog format since it was captured in its natural form. However, for this stage, it is necessary to convert the captured signal into digital format since the computer and the processor require scanning to perform its function. The original signal has to be subjected to three basic operations to digitize it: sampling, quantization, and coding.
\nSound, by nature, is an analog signal. It is produced by vibrations in the air that force the union of nearby molecules in the air by slightly raising its pressure. Such pressure changes reach the ear by vibrating the receptors and decoding to produce the sound. Some of the characteristics of the vibrations (in waveforms) are the following:
Amplitude: reflects the change in pressure from the highest peak to the minimum. A waveform with large amplitude has a volume of equal magnitude; otherwise, the volume is quieter.
Cycle: describes a single repeated sequence of pressure changes.
Frequency: describes the number of cycles produced in a second. If the frequency is high, the tone of the sound will be higher.
\nFigure 4 shows the representation of two analog signals of different frequencies each.
\nAnalogic signals with different frequencies.
If the frequency of a sound signals increases, the sound will be perceived as more acute because the wavelength decreases. Otherwise, when the frequency is low, the repetitions decrease, the wavelength increases, and, therefore, the sound tends to be a high-pitched tone.
\nThe first step to digitize the original signal consists of the sampling operation. The sampling of a sound signal consists of taking small representative pieces of the signal so that they are then encoded in binary digits to digitize them.
\nThe condition that the signal has to remain representative of the original must be considered. To cover the previous condition, the following equation known as Nyquist’s theorem must be followed:
\nIt is worth mentioning that if the sampling frequency is high, that is, if more samples are taken from the original signal in a certain time, the collection of significant parts for later digitization will allow a better fidelity of the original signal but now in a digital format and ready for computational processing.
\n\nFigure 5 represents the two signals shown in Figure 4 but now applying the sampling theorem; that is, small samples (pieces) representative of the signal are taken to be the “objects” to which binary codes will be assigned and thus digitized.
\nSampled analogic signals.
The quantization is the second step. It consists in assigning amplitude values to each sample obtained in the previous step, the foregoing in order to identify each sample that will be encoded.
\nFinally, and based on the amplitude assigned to each sample, a binary combination is correlated to each of them to be identified. Samples that have the same amplitude will have the same binary code.
\nStage C. In this step the adaptive filter algorithm will be implemented in the dsPIC3020F10 in order to perform the tests in real time. The processor will receive the signal in digital format (under previous scanning in Stage B) in order to process it to block the noise and allow the desired signal to pass through.
\nA DsPIC is a type of microprocessor known as a digital signal processor. It is responsible for real-time processing, a feature that is essential when non-tolerance of delays is required. Basically, a DsPIC [4] acquires a digital signal and processes it to improve it (in the case of audio, a clearer and sharper sound).
\nThe algorithm to be implemented is the noise amplitude modulation least mean square (NAMLMS) which consists in a modification of the LMS algorithm, the foregoing because the noise will have a modulation in its amplitude in order to eradicate it as well as possible.
\nThere is a wide variety of algorithms that can be classified into algorithms of low computational complexity with low convergence speed and high convergence speed algorithms with high computational cost. Some of the most used algorithms due to their low computational complexity are the averaged least squares algorithm (LMS, least mean square) and its normalization (NLMS). These algorithms have been successfully implemented in different systems. However, the convergence speed of these algorithms is slow. This means that the processing turns out to be so slow that it reduces the tests in real time, which would be not feasible for noise reduction applications especially in people suffering from hearing loss.
\nScheme of the proposal to cancel environmental noise.
The proposed scheme of Figure 6 consists of the following stages for the process:
Detection of the desired signal mixed with the ambient noise.
Attenuation of the environmental noise signal at a rate of 1/x, in order to reduce its amplitude and thus mitigate it. The above will happen only if the signal amplitude exceeds the allowed threshold. The frequency of it is not a factor to consider because we do not intend to distort the noise, only adaptively manipulate its sound intensity.
The desired signal is subtracted from the amplitude-modulated noise signal.
The signal obtained after the process is compared with respect to the desired one in order to obtain an error.
Based on the error obtained, the system is adapted to decide whether to reperform the process or has already converged to the permissible and minimum tolerated error.
Next, the process to follow for the mathematical analysis of the system is shown:
The desired signal with the adhered noise is picked up by the system. It is worth mentioning that the desired sound signal is contaminated by the noise prevailing in the environment:
where
\ns (n) = signal captured;
\nd (n) = desired signal;
\nv (n) = adhered environmental noise; and
\nx = modulation coefficient for attenuation.
\nIt is worth mentioning that the modulation coefficient will also be submitted to the adaptation algorithm in order to serve to attenuate the noise signal generated in the environment.
2. The correlation between both signals must be equal to zero. The above explains the fact that both are linearly independent:
\n
3. Subsequently, the signal obtained is processed by the adaptive filter to produce the output:
where
\nw (n) = the values of the adjustable coefficients of the adaptive filter; and.
\nk = iteration for each adaptation.
4. The filter output y (n) is subtracted from the main signal s (n). The above defines the error signal:
\n
5. The error signal is the one used to adjust the coefficient values of the adaptive filter and control loop around filtering operations and subtraction are related. Minimizing the mean square value of the error signal means maximizing the signal to noise ratio of the system output.
6. The adaptive filtering operation is perfect when:
In this case, the system output is noise-free, and the noise cancelation is perfect. Correspondingly, the signal to noise ratio of the output is infinitely large.
\nStage D. It consists of validating the filter response and also verifying that it inhibits unwanted frequencies (adhered noise). It is important to consider that the frequencies that will correspond to the desired signal must be the sounds that are desired and everything else must be blocked.
\nStage E. It is the inverse process of Stage B. The sound has an analog nature, so it must be converted to that format so that the receiver can decode it.
\nIn the environment, the desired sound signals are mixed with the unwanted signals (noise) [5]. Figure 7 shows the acquisition of the desired signal and the mixed noisy signal.
\nCombination between the original (desired) signal and the noise signal.
The blue graph shows the desired audio signal and used as a reference to compare what you want the system to throw at the output. The green signal is a type of noise captured in the environment, it could be said to be a random signal since it does not have a defined pattern. Finally, the red signal is the mixture of the previous ones.
\nThe objective is to submit the mixed signal (red) to the proposed adaptive system in order to attenuate the noise signal and allow the sound signal to pass through.
\nThe designed filter adapts to the conditions of the environment in which it is implemented. Next, the following figures will show, in parts, the analysis obtained for the proposed algorithm and its comparison with others established in the existing literature related to the subject.
\n\nFigure 8 shows the frequency response obtained for the passage of frequencies above the 10 kHz frequency which, on average, is the frequency at which a desirable sound oscillates. It is worth mentioning that, as a result of the adaptation, there is a slope that could establish a tolerance margin at lower frequencies.
\nFrequency response of the high-pass filter.
As can be seen in Figure 8, the response of the NAMLMS algorithm shows a slight hesitation in stability but achieves greater convergence with respect to the responses of the other algorithms. The proposed algorithm was based on the LMS algorithm that results in obvious instability and convergence, concluded, but showing latency.
\n\nFigure 9 shows the response for the part of the filter that allows low frequencies to pass through. The comparison with the responses of other filtering algorithms is visualized, and the rapid convergence and adaptation of the response offered by the proposed system stands out.
\nFrequency response of the low-pass filter.
\nFigure 10 shows the response of the system in general. It can be seen that the union of the two previous frequency responses generates the response of a frequency range through the filter. The objective is to suppress very low frequencies and very high frequencies that can be considered as noise and distortions that affect the human ear causing hearing loss.
\nFrequency response of the band pass filter.
\nFigure 11 shows the signal obtained as a response from the system. When compared with the reference signal, a correlation value of 0.912 is calculated which, according to the theory, indicates that there is a strong correlation between both signals and that, although the noise is slightly perceived, the desired signal is clearly perceived.
\nSignal resulting.
This chapter proposes an ambient noise cancelation system that allows to attenuate the noise that is mixed with the desired audible signals. Based on the results obtained, it is verified that the convergence of the algorithm is rapid relative to other existing ones, so it can be useful for use in new-generation cochlear implants or as treatments against symptoms of hearing loss.
\nSubjectively, the algorithm has a slight perception of adhered noise but does not affect its acoustic apparatus or the decoding of the messages of the desired sound signal.
\nObjectively, the correlation between the signal obtained after the respective system was calculated to the reference signal (desired), and an almost perfect result was achieved. Obviously a 100% correlation is not possible because the noise adhered to the desired sound and it is impossible not to modify some samples of said signal.
\nWe would like to thank the Universidad del Valle de México for providing us with the necessary means to carry out the research and provide part of the resources required.
\nOn the other hand, we also thank the Instituto Politécnico Nacional that has provided us with its facilities for experimentation and subject to real tests of the system I proposed. Without this valuable help, the development of this work would have been practically impossible.
\nOpen Access publishing helps remove barriers and allows everyone to access valuable information, but article and book processing charges also exclude talented authors and editors who can’t afford to pay. The goal of our Women in Science program is to charge zero APCs, so none of our authors or editors have to pay for publication.
",metaTitle:"What Does It Cost?",metaDescription:"Open Access publishing helps remove barriers and allows everyone to access valuable information, but article and book processing charges also exclude talented authors and editors who can’t afford to pay. The goal of our Women in Science program is to charge zero APCs, so none of our authors or editors have to pay for publication.",metaKeywords:null,canonicalURL:null,contentRaw:'[{"type":"htmlEditorComponent","content":"We are currently in the process of collecting sponsorship. If you have any ideas or would like to help sponsor this ambitious program, we’d love to hear from you. Contact us at info@intechopen.com.
\\n\\nAll of our IntechOpen sponsors are in good company! The research in past IntechOpen books and chapters have been funded by:
\\n\\nWe are currently in the process of collecting sponsorship. If you have any ideas or would like to help sponsor this ambitious program, we’d love to hear from you. Contact us at info@intechopen.com.
\n\nAll of our IntechOpen sponsors are in good company! The research in past IntechOpen books and chapters have been funded by:
\n\n